Pharmaceutics,
Год журнала:
2023,
Номер
15(7), С. 1931 - 1931
Опубликована: Июль 11, 2023
Central
nervous
system
(CNS)
diseases
are
currently
a
major
challenge
in
medicine.
One
reason
is
the
presence
of
blood–brain
barrier,
which
significant
limitation
for
used
medicinal
substances
that
characterized
by
high
molecular
weight
and
short
half-life.
Despite
application
nanotechnology,
there
still
problem
targeting
occurrence
systemic
toxicity.
Viral
vectors
virus-like
particles
(VLPs)
may
provide
promising
solution
to
these
challenges.
Their
small
size,
biocompatibility,
ability
carry
substances,
specific
neural
cells
make
them
useful
research
when
formulating
new
generation
biological
carriers.
Additionally,
possibility
genetic
modification
has
potential
gene
therapy.
Among
most
viral
adeno-associated
viruses,
adenoviruses,
retroviruses.
This
due
their
natural
tropism
cells,
as
well
surface
modification.
Moreover,
VLPs
devoid
infectious
material
favor
increasing
capacity
also
leading
way
on
drug
delivery
systems.
The
aim
this
study
review
recent
reports
use
treatment
selected
CNS
diseases.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Фев. 1, 2024
Vaccines
have
proven
effective
in
the
treatment
and
prevention
of
numerous
diseases.
However,
traditional
attenuated
inactivated
vaccines
suffer
from
certain
drawbacks
such
as
complex
preparation,
limited
efficacy,
potential
risks
others.
These
limitations
restrict
their
widespread
use,
especially
face
an
increasingly
diverse
range
With
ongoing
advancements
genetic
engineering
vaccines,
DNA
emerged
a
highly
promising
approach
both
diseases
acquired
While
several
demonstrated
substantial
success
animal
models
diseases,
challenges
need
to
be
addressed
before
application
human
subjects.
The
primary
obstacle
lies
absence
optimal
delivery
system,
which
significantly
hampers
immunogenicity
vaccines.
We
conduct
comprehensive
analysis
current
status
by
focusing
on
viral
non-viral
systems,
they
play
crucial
roles
exploration
novel
provide
evaluation
strengths
weaknesses
based
our
critical
assessment.
Additionally,
review
summarizes
most
recent
breakthroughs
pre-clinical
clinical
studies,
highlighting
for
further
trials
this
rapidly
evolving
field.
Influenza and Other Respiratory Viruses,
Год журнала:
2024,
Номер
18(3)
Опубликована: Март 1, 2024
ABSTRACT
Every
year,
influenza
virus
infections
cause
significant
morbidity
and
mortality
worldwide.
They
pose
a
substantial
burden
of
disease,
in
terms
not
only
health
but
also
the
economy.
Owing
to
ability
viruses
continuously
evolve,
annual
seasonal
vaccines
are
necessary
as
prophylaxis.
However,
current
against
strains
have
limited
effectiveness
require
yearly
reformulation
due
undergoing
antigenic
drift
or
shift.
Vaccine
mismatches
common,
conferring
suboptimal
protection
outbreaks,
threat
next
pandemic
continues
loom.
Therefore,
there
is
great
need
develop
universal
vaccine
(UIV)
capable
providing
broad
durable
all
strains.
In
quest
UIV
that
would
obviate
for
vaccination
formulation,
multitude
strategies
currently
underway.
Promising
approaches
include
targeting
highly
conserved
epitopes
haemagglutinin
(HA),
neuraminidase
(NA),
M2
extracellular
domain
(M2e)
internal
proteins
virus.
The
identification
characterization
broadly
neutralizing
antibodies
(bnAbs)
regions
viral
HA
protein,
particular,
provided
important
insight
into
novel
designs
platforms.
This
review
discusses
presently
under
development,
with
an
emphasis
on
those
stalk
recent
technological
advancements
used
future
prospects
its
advantages,
developmental
obstacles
potential
shortcomings.
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2025,
Номер
13
Опубликована: Март 12, 2025
The
advent
of
mRNA
vaccines,
accelerated
by
the
global
response
to
COVID-19
pandemic,
marks
a
transformative
shift
in
vaccine
technology.
In
this
article,
we
discuss
development,
current
applications,
and
prospects
vaccines
for
both
prevention
treatment
infectious
diseases
oncology.
By
leveraging
capacity
encode
antigens
within
host
cells
directly,
provide
versatile
scalable
platform
suitable
addressing
broad
spectrum
pathogens
tumor-specific
antigens.
We
highlight
recent
advancements
design,
innovative
delivery
mechanisms,
ongoing
clinical
trials,
with
particular
emphasis
on
their
efficacy
combating
diseases,
such
as
COVID-19,
Zika,
influenza,
well
emerging
potential
cancer
immunotherapy.
also
address
critical
challenges,
including
stability,
optimization
immune
responses,
broader
issue
accessibility.
Finally,
review
strategies
advancing
next-generation
aim
overcoming
limitations
technology
enhancing
preventive
therapeutic
approaches
oncological
diseases.
Pharmaceutics,
Год журнала:
2023,
Номер
15(11), С. 2623 - 2623
Опубликована: Ноя. 14, 2023
Biomimetic
delivery
systems
(BDSs),
inspired
by
the
intricate
designs
of
biological
systems,
have
emerged
as
a
groundbreaking
paradigm
in
nanomedicine,
offering
unparalleled
advantages
therapeutic
delivery.
These
encompassing
platforms
such
liposomes,
protein-based
nanoparticles,
extracellular
vesicles,
and
polysaccharides,
are
lauded
for
their
targeted
delivery,
minimized
side
effects,
enhanced
outcomes.
However,
translation
BDSs
from
research
settings
to
clinical
applications
is
fraught
with
challenges,
including
reproducibility
concerns,
physiological
stability,
rigorous
efficacy
safety
evaluations.
Furthermore,
innovative
nature
demands
reevaluation
evolution
existing
regulatory
ethical
frameworks.
This
review
provides
an
overview
delves
into
multifaceted
translational
challenges
present
emerging
solutions,
underscored
real-world
case
studies.
Emphasizing
potential
redefine
healthcare,
we
advocate
sustained
interdisciplinary
collaboration
research.
As
our
understanding
deepens,
future
appears
promising,
focus
on
personalized
medicine
refined
patient-specific
systems.
Reviews in Medical Virology,
Год журнала:
2023,
Номер
34(1)
Опубликована: Дек. 20, 2023
Abstract
Nowadays,
viruses
are
not
only
seen
as
causative
agents
of
viral
infectious
diseases
but
also
valuable
research
materials
for
various
biomedical
purposes,
including
recombinant
protein
production.
When
expressed
in
living
or
cell‐free
expression
systems,
structural
proteins
self‐assemble
into
virus‐like
particles
(VLPs).
Mimicking
the
native
form
and
size
lacking
genetic
material,
VLPs
safe
highly
immunogenic
thus
can
be
exploited
to
develop
antiviral
vaccines.
Some
vaccines
based
on
against
pathogens
have
already
been
licenced
human
use
available
commercial
market,
latest
which
is
a
VLP‐based
vaccine
protect
novel
Coronavirus.
Despite
success
popularity
VLP
subunit
vaccines,
many
more
still
different
stages
design,
production,
approval.
There
challenges
that
require
addressed
future
before
this
surface
display
system
widely
used
an
effective
strategy
combating
diseases.
In
review,
we
highlight
produce
VLPs,
emphasising
their
intrinsic
properties,
classification,
main
host
systems.
We
compiled
recent
scientific
literature
about
underline
advances
application
preventing
fighting
virulent
pathogens.
Finally,
presented
key
possible
solutions
Separation and Purification Technology,
Год журнала:
2024,
Номер
340, С. 126673 - 126673
Опубликована: Фев. 8, 2024
Chimeric
virus-like
particles
formed
by
the
co-expression
of
HIV-1
gag
capsid
protein
and
surface
proteins
from
other
viruses
can
be
used
as
a
platform
for
production
wide
range
viral
vaccines.
These
rapidly
produced
in
an
insect
cell
culture
using
baculovirus
expression
vector
system.
However,
variety
different
process-related
impurities
such
host
proteins,
double
stranded
DNA,
chromatin,
structurally
similar
bionanoparticles
like
extracellular
vesicles
are
present
harvested
supernatant
complicate
chromatographic
purification
steps.
Heparan
sulfate
is
first
entry
point
lot
enveloped
into
cell.
Taking
advantage
this
functional
property,
its
sub-variant,
glycosaminoglycan
heparin
immobilized
on
chromatography
media
universal
tool
separation
particles.
A
process
was
developed
consisting
clarification
membrane
filtration,
pre-purification
step
core–shell
bead
flow-through
with
Capto™
Core
700,
followed
affinity
Heparin.
The
combination
700
Heparin
allows
direct
load
material
second
without
buffer
exchange
between.
In
addition,
lengthy
screening,
required
ion
multimodal
chromatography,
omitted.
Linear
salt
gradient
elution
enabled
baculovirus.
platformability
demonstrated
expressing
influenza
virus
hemagglutinin
or
neuraminidase,
SARS-CoV-2
spike
antigens
particle
co-expressed
protein.
Western
blotting,
DNA
assays,
TCID50
(for
residual
baculovirus),
mass
spectrometry,
multi-angle
light
scattering
nanoparticle
tracking
analysis
were
to
characterize
fractions
obtained
during
purification.
profile
all
tested
deviations
could
explained
batch-to-batch
variations
differences
productivity
constructs.
Double
reduced
7
–
36
ng/109
content
below
limit
quantification;
main
product
fraction
average
seven-fold
reduction
yield
9
%
−
14
bound
concentration
1.4
1.8
×
1010
particles/mL
eluate
achieved
meeting
requirements
vaccine.
Accordingly,
suitable
downstream
chimeric
gag-based
VLP
products.
Frontiers in Cellular and Infection Microbiology,
Год журнала:
2024,
Номер
14
Опубликована: Июнь 26, 2024
The
Coronavirus
Disease
2019
(COVID-19)
pandemic,
caused
by
the
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
has
incurred
devastating
human
and
economic
losses.
Vaccination
remains
most
effective
approach
for
controlling
COVID-19
pandemic.
Nonetheless,
sustained
evolution
of
SARS-CoV-2
variants
provoked
concerns
among
scientific
community
regarding
development
next-generation
vaccines.
Among
these,
given
their
safety,
immunogenicity,
flexibility
to
display
varied
native
epitopes,
virus-like
particle
(VLP)-based
vaccines
represent
one
promising
In
this
review,
we
summarize
advantages
characteristics
VLP
platforms,
strategies
antigen
display,
current
clinical
trial
progress
based
on
platforms.
Importantly,
experience
lessons
learned
from
provide
insights
into
prevent
future
pandemics
other
epidemics.
Langmuir,
Год журнала:
2024,
Номер
40(9), С. 4762 - 4771
Опубликована: Фев. 22, 2024
The
antigen
density
on
the
surface
of
HIV-based
virus-like
particles
(VLPs)
plays
a
crucial
role
in
improvement
HIV
vaccine
potency.
VLPs
consist
dense
protein
core,
which
is
surrounded
by
lipid
bilayer
and
whose
usually
decorated
with
antigenic
glycoproteins.
successful
downstream
processing
these
challenging,
high-resolution
cost-efficient
purification
has
not
yet
been
achieved.
Chromatography,
one
major
unit
operations
involved
VLP
strategies,
carried
out
means
ion
exchangers
or
ion-exchange
membranes.
Understanding
electrokinetic
behavior
may
help
to
improve
adjustment
efficiency
corresponding
chromatographic
processes.
In
this
study,
we
investigated
electrokinetics
aggregation
both
undecorated
interpreted
data
from
perspective
soft
particle
model
developed
Ohshima
(OSPM),
fails
fully
predict
studied
VLPs.
Post-Ohshima
literature,
particularly
multilayer
Langlet
et
al.,
provides
an
alternative
theoretical
framework
overcome
limits
OSPM.
We
finally
hypothesized
that
electrophoretic
mobility
controlled
electrohydrodynamic
interplay
between
envelope
glycoproteins,
bilayer,
Gag
envelope.
